These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35356486)

  • 21. Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus.
    Pyykkö OT; Lumela M; Rummukainen J; Nerg O; Seppälä TT; Herukka SK; Koivisto AM; Alafuzoff I; Puli L; Savolainen S; Soininen H; Jääskeläinen JE; Hiltunen M; Zetterberg H; Leinonen V
    PLoS One; 2014; 9(3):e91974. PubMed ID: 24638077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid β.
    Reinsfelt B; Westerlind A; Blennow K; Zetterberg H; Ricksten SE
    Acta Anaesthesiol Scand; 2013 Jan; 57(1):82-8. PubMed ID: 22998015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process.
    Sjögren M; Davidsson P; Gottfries J; Vanderstichele H; Edman A; Vanmechelen E; Wallin A; Blennow K
    Dement Geriatr Cogn Disord; 2001; 12(4):257-64. PubMed ID: 11351137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid biomarkers of β-amyloid metabolism and neuronal damage in epileptic seizures.
    Shahim P; Rejdak R; Ksiazek P; Blennow K; Zetterberg H; Mattsson N; Rejdak K
    Eur J Neurol; 2014 Mar; 21(3):486-91. PubMed ID: 24372994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy.
    Sembill JA; Lusse C; Linnerbauer M; Sprügel MI; Mrochen A; Knott M; Engelhorn T; Schmidt MA; Doerfler A; Oberstein TJ; Maler JM; Kornhuber J; Lewczuk P; Rothhammer V; Schwab S; Kuramatsu JB
    Brain Commun; 2023; 5(3):fcad159. PubMed ID: 37389304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study.
    Lauridsen C; Sando SB; Shabnam A; Møller I; Berge G; Grøntvedt GR; Bakken IJ; Salvesen Ø; Bråthen G; White LR
    Front Aging Neurosci; 2016; 8():30. PubMed ID: 26973507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
    Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
    CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
    Savage MJ; Holder DJ; Wu G; Kaplow J; Siuciak JA; Potter WZ;
    J Alzheimers Dis; 2015; 46(2):431-40. PubMed ID: 25790831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Inflammasome Adaptor Protein ASC in Mild Cognitive Impairment and Alzheimer's Disease.
    Scott XO; Stephens ME; Desir MC; Dietrich WD; Keane RW; de Rivero Vaccari JP
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease.
    Mohs RC; Beauregard D; Dwyer J; Gaudioso J; Bork J; MaGee-Rodgers T; Key MN; Kerwin DR; Hughes L; Cordell CB;
    Alzheimers Dement; 2024 Apr; 20(4):2752-2765. PubMed ID: 38415908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.
    Hock C; Golombowski S; Müller-Spahn F; Naser W; Beyreuther K; Mönning U; Schenk D; Vigo-Pelfrey C; Bush AM; Moir R; Tanzi RE; Growdon JH; Nitsch RM
    Eur Neurol; 1998; 39(2):111-8. PubMed ID: 9520072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.
    Lewczuk P; Popp J; Lelental N; Kölsch H; Maier W; Kornhuber J; Jessen F
    J Alzheimers Dis; 2012; 28(1):119-25. PubMed ID: 21971403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
    Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
    J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.